Skip to main content

Table 2 Cox regression hazard ratios for CTC count ≥ 5 versus < 5, and presence versus absence of CTC clusters

From: Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial

  PFS P value OS P value
HR (95% CI) HR (95% CI)
Baseline
 Unadjusted
  CTC ≥ 5 1.68 (1.17–2.42) 0.005 2.52 (1.58–4.01) < 0.001
  Clusters present 1.54 (1.00–2.40) 0.05 2.23 (1.35–3.69) 0.002
 Adjusteda
  CTC ≥ 5 2.30 (1.43–3.71) 0.001 3.92 (2.09–7.36) < 0.001
  Clusters present 2.64 (1.46–4.78) 0.001 4.07 (1.99–8.31) < 0.001
One monthb
 Unadjusted
  CTC ≥ 5 2.17 (1.43–3.30) < 0.001 4.38 (2.63–7.30) < 0.001
  Clusters present 3.23 (1.70–-6.14) < 0.001 4.52 (2.24–9.15) < 0.001
 Adjustedc
  CTC ≥ 5 2.30 (1.23–4.32) 0.009 4.39 (2.04–9.43) < 0.001
  Clusters present 3.37 (1.51–7.55) 0.003 5.67 (2.30–13.95) < 0.001
Three monthsb
 Unadjusted
  CTC ≥ 5 2.24 (1.24–4.03) 0.07 3.28 (1.76–6.12) < 0.001
  Clusters present 3.16 (1.60–6.22) 0.001 3.35 (1.68–6.68) 0.001
 Adjustedc
  CTC ≥ 5 2.95 (1.44–6.06) 0.003 5.93 (2.62–13.42) < 0.001
  Clusters present 3.04 (1.35–6.84) 0.007 3.55 (1.44–8.77) 0.006
Six monthsb
 Unadjusted
  CTC ≥ 5 4.33 (2.10–8.93) < 0.001 7.74 (3.52–16.99) < 0.001
  Clusters present 6.48 (2.26–18.56) 0.001 9.92 (3.30–29.78) < 0.001
 Adjustedc
  CTC ≥ 5 6.43 (2.30–17.94) < 0.001 15.72 (3.79–65.17) < 0.001
  Clusters present 7.17 (2.03–25.36) 0.002 21.65 (5.06–92.63) < 0.001
  1. Abbreviations: PFS progression-free survival, OS overall survival, HR hazard ratio, CTC circulating tumor cell
  2. aAdjusted for the variables included in the clinicopathological model (Additional file 3)
  3. bAssessed by landmark analysis
  4. cAdjusted for the variables included in the clinicopathological model (Additional file 3) and for baseline CTC count (< 5 vs ≥ 5)